Greenwich LifeSciences, Inc.
A clinical-stage biopharma developing immunotherapies to prevent cancer recurrence.
GLSI | US
Overview
Corporate Details
- ISIN(s):
- US3968791083
- LEI:
- Country:
- United States of America
- Address:
- 3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
- Sector:
- Manufacturing
Description
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies to prevent cancer recurrence. Its lead product candidate is GLSI-100, an immunotherapy vaccine designed to prevent the recurrence of breast cancer in HER2-positive patients who have completed prior treatments. GLSI-100 combines GP2, a peptide derived from the HER2/neu protein, with the immune adjuvant GM-CSF to stimulate an immune response. A completed Phase IIb clinical trial showed a significant reduction in the five-year recurrence rate with a well-tolerated safety profile. The company is currently advancing GLSI-100 in a global, Fast Track designated Phase III clinical trial, Flamingo-01, to further evaluate its safety and efficacy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Greenwich LifeSciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
